Major depressive disorder is a serious clinical condition marked by ongoing sadness and reduced interest in daily activities. It affects at least ten percent of people in the United States during their lifetime and generates more than two hundred ten billion dollars each year in medical expenses and lost productivity.
Because the disorder stems from a complex blend of genetic, psychological and biological elements, recognizing its subtypes could improve treatment design.
A new preprint study investigated two opposing patterns of energy-related symptoms to clarify underlying mechanisms. The work introduces an immunometabolic model that addresses inconsistencies in current diagnostic standards.
Present criteria count opposite signs such as weight gain or loss and increased or decreased sleep as equivalent for diagnosis. While this promotes uniformity, it may encourage generic treatments that overlook individual differences.
People given the same diagnosis frequently show varied symptom patterns that may reflect partly separate biological pathways.
Researchers performed three genome-wide association analyses covering more than four hundred sixty thousand individuals of European ancestry. They compared groups defined by hypersomnia with weight gain, insomnia with weight loss, and a mixed category.
The results indicated two distinct biological profiles. The hypersomnia and weight gain group displayed the highest body mass index, greater recurrence, earlier onset, more functional impairment and additional medical conditions.
Twenty-seven genome-wide loci were found in total. Four were linked to the first group, ten to the second group and thirteen to the mixed group.
The first subtype correlated positively with metabolic and inflammatory markers while the second showed negative correlations with the same traits and possible ties to schizophrenia.
These patterns suggest different pathophysiological routes that may require tailored therapeutic strategies.
